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Introduction: The potential for pathogenic organisms to be transmitted between CF
patients is increasingly being recognised, leading to the recommendation of strict
segregation of cohorts of infected patients from each other. However, one route of
cross infection involves the communal use of equipment, such as the spirometer
essential in the measurement of pulmonary function. We audited the practises of
CF units in the UK aimed at avoiding such avenues for cross infection.
Method: A telephone survey of 29 pulmonary function departments (18 adult) of
the 49 serving large CF clinics (>50 patients) as listed by the UK CF Trust.
Results: During pulmonary function testing, although 13 units (8 adult) used a
different device for each CF patient, only 7 (5) used bacterial ﬁlters routinely in the
spirometer. As regards segregation of patients when performing pulmonary function
testing, 16 (9) used different rooms in the department, 4 (3) performed tests on the
ward, 10 (6) separated patients by time of day, and 9 (6) by different days of the
week. One adult department did not carry out any segregation or hygiene measures
in relation to CF patients, and another only had a segregation policy for MRSA
cases.
Conclusions: This audit shows a wide variation in the hygienic use of spirometric
equipment for CF patients, and an alarming lack of adequate segregation measures
in many pulmonary function departments with a consequent potential for cross
infection if transmissible strains are present. An education campaign may be
necessary to improve this aspect of patient care.
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Background: The most sensitive method to monitor progression of CF lung disease
is by Computed Tomography (CT) scans. Current CT protocols include low dose
(0.6mSv) inspiratory (LDin) and ultra low dose (0.15mSv) expiratory (ULDexp)
volumetric scans. It was never investigated whether ULDexp scans alone might
sufﬁce.
Purpose: To evaluate whether ULDexp CT scans are sufﬁcient to monitor progres-
sion of CF lung disease.
Methods: 20 children with CF contributed one LDin and one ULDexp CT scan. All
scans were scored with the Brody-II scoring system which scores bronchiectasis,
airway wall thickening, mucus plugging and opacities for pattern and severity. All
scans were scored in random order by a single experienced observer.
Statistics: Assessment of intraobserver agreement; intraclass correlation coefﬁ-
cients (ICC) and Bland-Altman plots.
Results: Median age (range) was 12.6 (6.3–20.3) years, FEV1 100%pred (46–
127) and FVC 98.5%pred (61–123). Excellent agreement was found between LDin
and ULDexp Brody-II total CT scores (ICC 0.96), bronchiectasis (0.95), airway
wall thickening (0.90), mucus plugging (0.88) and opacities (0.84). Intraobserver
agreement was good (ICC 0.77– 0.92). Bland-Altman plots showed that differences
in scores were not dependent on the score magnitude.
Conclusions: This study shows that LDin and ULDexp CT scores match. This
strongly suggests that ULDexp volumetric scans could be sufﬁcient to monitor
progression of CF lung disease.
Supported by: The Sophia CF research fund, the Dutch CF foundation (NCFS) and
the Italian CF fund (IERFC).
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Chronic cough disturbs daily life and interrupts sleep. Most CF patients note cough
as a symptom, yet quantitation of cough has seldom been done.
We analyzed cough using the VivoMetrics Lifeshirt® (LS), which collects data
from chest wall motion transducers and a throat microphone for computer analysis.
FEV1 and FVC were assessed by spirometry, and patients completed a symptom
survey.
Patients included 19 adults not in CF exacerbation (M:F = 10:9; median [range]
age = 26 [19−57] years; median [range] % predicted FEV1 and FVC = 65 [44–
106]% and 80 [58–112]%; Pseudomonas airway colonization = 17/19 [89%];
pancreatic insufﬁciency = 17/19 [89%]). There was occasional neck pressure due
to the throat microphone, but compliance was good, with cough data collected for
a median [range] of 24 [23−24] hours. Median [range] of cough frequency was
643 [324–1569] coughs/day, or 27 [14−65] coughs/hour, with frequency during
daytime (0700–2300 hours) of 21 [9−89] and at nighttime of 24 [8−98] coughs/hour
(p = 0.21, paired t test). Median [range] of cough intensity was 1086 [422–2005]mV,
with daytime intensity of 834 [332–2562] and nighttime intensity of 886 [386–
2213]mV (p = 0.25, paired t-test). Symptom surveys (1: minimal to 4: frequent
coughing/wakes from sleep) showed a median [range] score of 2 [1−3] for daytime
and 1 [1−3] for nighttime coughing. Cough frequency tended to increase with lower
FEV1 and greater age.
CF patients cough frequently, day and night, but underreport cough, perhaps due
to acclimation to the chronicity of the symptom. LS quantitation appears superior
to subjective cough assessment methods and may offer a clinically meaningful
outcome measure of how patients feel and function for use in CF therapeutic trials.
Supported by: PTC Therapeutics.
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Day or early morning hypercapnia or the inability to oxygenate patients without
signiﬁcant rises in CO2 are indications for non-invasive ventilation (NIV). To
investigate potential future NIV requirement, overnight O2 and CO2 status were
examined during acute hospital admissions.
Methods: All willing patients admitted over 4 months particpated. On admission
ear lobe sensors (Tosca™500 system) were applied. On application (late pm) and
removal (early am), we recorded the tcPCO2, SpO2 values and measured ear lobe
blood gases (ELG).
Results: Data on the 28 (15 male) patients not already on O2 or NIV is presented.
Mean (range), age 27.2 (18.44) yrs, BMI 20.4 kg/m2 (13.8, 25.5), CRP (median)
10.5 (0.64), FEV1 1.48l/s (0.55, 3.1), FEV1 %pred. 42.2 (16.3, 96.4). Table 1
compares the tcPCO2, PaCO2 and PaO2 data. 17 patients had normal overnight
SpO2 and tcPCO2 traces. 2 studies identiﬁed hypoxia (SpO2 <90% for >1hour)
without signiﬁcant rise in tcPCO2, 9 studies identiﬁed hypercapnia without hypoxia,
3 mild (tcPCO2 >6kPa for >1hour but <4hours) and 6 signiﬁcant (tcPCO2 >6kPa
for >4 hours). The FEV1% was lower in the latter group: 29.4 (16.3, 55.2) SD 14.6
compared to the other 22 patients 45.7 (23.9, 96.4) SD 16.5.
Conclusions: tcPCO2 is in close agreement with PaCO2. Preliminary data using
the Tosca™500 identiﬁes groups with different nocturnal ventilatory status in acute
adult CF patients.
Supported by: Radiometer Limited – Respironics (UK) Limited.
Table 1
PM AM mean difference (95%CI) p
tcPCO2 5.09 (4.3, 5.7) 5.30 (4.0, 6.8) −0.21 (−0.46, 0.04) 0.098
PaCO2 4.97 (4.1, 5.8) 5.2 (4.0, 6.2) −0.24 (−0.43, −0.05) 0.015
PaO2 9.16 (7.9, 10.8) 9.2 (6.6, 11.7) −0.07 (−0.42, 0.29) 0.703
difference mean tcPCO2 and PaCO2
(95%CI)
0.12 (0.036, 0.202)
p = 0.007
0.09 (−0.06, 0.24)
p = 0.235
95% limits of agreement −0.31, 0.55 −0.69,0.88
